Previous 10 | Next 10 |
ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced today that it has entered into a...
Gainers: [[OCC]] +40.5%. [[MRUS]] +27.2%. [[DRTT]] +22.2%. [[OEC]] +13.9%. [[WDFC]] +13.8%.Losers: [[SRPT]] -51.6%. [[SLDB]] -24.5%. [[BNGO]] -11.6%. [[UUU]] -9.7%. [[CERC]] -7.2%. For further details see: SRPT, BNGO, WDFC and MRUS among after-hours movers
Cerecor (CERC) shares traded 12% down after-hours after announcing its offer for sale shares to a certain investor in lieu thereof, pre-funded warrants to purchase shares of common stock, in an underwritten public offering; underwriters granted 30-day option to purchase up...
ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced today that it intends to offer f...
Cerecor ([[CERC]] +13.6%) announces results from its exploratory Phase 2 proof of concept trial of monoclonal antibody CERC-002 in patients hospitalized with COVID-19 associated pneumonia and mild-to-moderate acute respiratory distress syndrome.The trial included 83 patients who wer...
Aileron Therapeutics (ALRN) +73%.Broadway Financial Corporation (BYFC) +55% after regulatory approvals for merger with CFBanc Corporation.Atlantic American Corporation (AAME) +43%.Marker Therapeutics (MRKR) +30% after FDA lifted the partial clinical hold on it's Phase 2 trial.Cyclo ...
COVID-19 ARDS patients treated with a single dose of the anti-LIGHT monoclonal antibody CERC-002 demonstrated robust improvement in the primary endpoint (proportion of patients alive and free of respiratory failure over the 28-day study period) compared to placebo (n=62, odds ratio [OR]...
Cerecor ([[CERC]] +5.8%) announced that its Investigational New Drug Application to study the use of CERC-007 to treat Still’s disease has been accepted by the FDA and is now open.CERC-007 is a high affinity, fully human anti-IL-18 monoclonal antibody (mAb).The first study will be...
ROCKVILLE, Md. and CHESTERBROOK, Pa., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that its Investigational New Drug Ap...
Cerecor (CERC) has dosed its first patient in a Phase 1b clinical trial of CERC-007, a fully human anti-IL-18 monoclonal antibody (mAb) being developed for patients with relapsed or refractory multiple myeloma ((MM)).The study will determine the recommended Phase 2 dose, safety and preliminar...
News, Short Squeeze, Breakout and More Instantly...
Cerecor Inc. Company Name:
CERC Stock Symbol:
NASDAQ Market:
WAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Mittie Doyle, MD, FACR has joined the Company as its Chief Medical Officer. “We are thrilled to have Mittie join and grow our leadership team at an exciting...
Following FDA review, Avalo’s IND application for AVTX-009 is active allowing Avalo to proceed with its Phase 2 trial (LOTUS) to evaluate the efficacy and safety of AVTX-009 in patients with hidradenitis suppurativa WAYNE, Pa. and ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Ava...
WAYNE, Pa. and ROCKVILLE, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present on the Novel Immunological Mechanisms for Dermatological Disorders Panel being held at...